Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd | GLMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.395 | 04:43:18 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.395 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.26 - 14.175 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.395 | USD |
Galmed Pharmaceuticals Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 655.2k | 1.68M | - | 0 | -17.87M | -10.63 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Galmed Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLMD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.3557 | 0.4174 | 0.3206 | 0.3727879 | 104,712 | 0.0393 | 11.05% |
| 1 Month | 0.40 | 0.4343 | 0.26 | 0.3870169 | 397,927 | -0.005 | -1.25% |
| 3 Months | 0.77 | 0.8749 | 0.26 | 0.429632 | 190,526 | -0.375 | -48.7% |
| 6 Months | 4.30 | 5.47 | 0.26 | 1.31 | 227,535 | -3.91 | -90.81% |
| 1 Year | 4.575 | 14.175 | 0.26 | 3.80 | 208,968 | -4.18 | -91.37% |
| 3 Years | 55.35 | 93.75 | 0.26 | 29.07 | 189,765 | -54.96 | -99.29% |
| 5 Years | 127.20 | 146.10 | 0.26 | 43.12 | 150,424 | -126.81 | -99.69% |
Galmed Pharmaceuticals Description
| Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |
